NovaBridge gains FDA fast track status for bispecific antibody givastomig
NovaBridge Biosciences (NASDAQ:NBP) received FDA Fast Track Designation for its bispecific antibody givastomig to treat advanced gastric adenocarcinoma expressing Claudin 18.2 protein levels.










